| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.21▲ | 4.12▲ | 4.13▲ | 4.21▲ | 4.48▼ |
| MA10 | 4.16▲ | 4.10▲ | 4.16▲ | 4.25▲ | 4.76▼ |
| MA20 | 4.12▲ | 4.15▲ | 4.18▲ | 4.43▼ | 5.77▼ |
| MA50 | 4.09▲ | 4.17▲ | 4.14▲ | 4.78▼ | 9.88▼ |
| MA100 | 4.15▲ | 4.14▲ | 4.43▼ | 6.04▼ | 9.55▼ |
| MA200 | 4.16▲ | 4.41▼ | 4.52▼ | 9.55▼ | 11.70▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.018▲ | 0.005▲ | -0.002▼ | -0.004▼ | 0.063▲ |
| RSI | 76.486▲ | 59.685▲ | 55.958▲ | 44.351▼ | 28.710▼ |
| STOCH | 87.026▲ | 45.094 | 28.200 | 30.335 | 22.628 |
| WILL %R | 0.000▲ | 0.000▲ | -23.333▲ | -74.375 | -86.379▼ |
| CCI | 134.770▲ | 177.291▲ | 80.102 | -38.123 | -102.195▼ |
|
Tuesday, April 29, 2025 07:01 AM
YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
|
|
Sunday, April 27, 2025 02:25 PM
Y-mAbs Therapeutics (YMAB) announced the presentation of preclinical and translational pharmacokinetics, PK, data of CD38-SADA in a poster at ...
|
|
Sunday, April 27, 2025 12:10 PM
Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 02/05/25 | 4.24 | 4.25 | 4.21 | 4.25 | 8,777 |
| 01/05/25 | 4.17 | 4.29 | 4.02 | 4.11 | 203,900 |
| 30/04/25 | 4.14 | 4.33 | 4.10 | 4.25 | 169,600 |
| 29/04/25 | 4.15 | 4.25 | 4.10 | 4.21 | 136,141 |
| 28/04/25 | 4.08 | 4.265 | 4.08 | 4.23 | 120,647 |
| 25/04/25 | 4.09 | 4.12 | 3.9401 | 4.10 | 106,043 |
| 24/04/25 | 3.99 | 4.14 | 3.915 | 4.13 | 216,435 |
| 23/04/25 | 4.37 | 4.40 | 4.11 | 4.12 | 181,486 |
| 22/04/25 | 4.43 | 4.615 | 3.84 | 4.26 | 562,547 |
| 21/04/25 | 4.63 | 4.92 | 4.59 | 4.82 | 141,837 |
|
|
||||
|
|
||||
|
|